WO2006066079A2 - Pyridazinone compounds - Google Patents
Pyridazinone compounds Download PDFInfo
- Publication number
- WO2006066079A2 WO2006066079A2 PCT/US2005/045588 US2005045588W WO2006066079A2 WO 2006066079 A2 WO2006066079 A2 WO 2006066079A2 US 2005045588 W US2005045588 W US 2005045588W WO 2006066079 A2 WO2006066079 A2 WO 2006066079A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- heterocyclyl
- nhc
- aryl
- Prior art date
Links
- WOGXHNJBKGZMHV-UHFFFAOYSA-N CC(C(N)=O)OC Chemical compound CC(C(N)=O)OC WOGXHNJBKGZMHV-UHFFFAOYSA-N 0.000 description 1
- JVMJIRSFFBNDFN-UHFFFAOYSA-N CC(Nc1c2[s]cc1)=NS2(=O)=O Chemical compound CC(Nc1c2[s]cc1)=NS2(=O)=O JVMJIRSFFBNDFN-UHFFFAOYSA-N 0.000 description 1
- FDWRKMPNEIXNOE-UHFFFAOYSA-N CC(Nc1c2cccc1)=NS2(=O)=O Chemical compound CC(Nc1c2cccc1)=NS2(=O)=O FDWRKMPNEIXNOE-UHFFFAOYSA-N 0.000 description 1
- NKKREMMBGZRZTR-UHFFFAOYSA-N CC(Nc1c2cncc1)=NS2(=O)=O Chemical compound CC(Nc1c2cncc1)=NS2(=O)=O NKKREMMBGZRZTR-UHFFFAOYSA-N 0.000 description 1
- UUXHICUVBOTXQS-UHFFFAOYSA-N CCC(C(N)=O)O Chemical compound CCC(C(N)=O)O UUXHICUVBOTXQS-UHFFFAOYSA-N 0.000 description 1
- NCCHARWOCKOHIH-UHFFFAOYSA-N CNC(c1ccccc1)=O Chemical compound CNC(c1ccccc1)=O NCCHARWOCKOHIH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
- Hepatitis C is a major health problem world- wide.
- the World Health Organization estimates that 170 million people are chronic carriers of the hepatitis C virus (HCV), with 4 million carriers in the United States alone.
- HCV infection accounts for 40% of chronic liver disease and HCV disease is the most common cause for liver transplantation.
- HCV infection leads to a chronic infection and about 70% of persons infected will develop chronic histological changes in the liver (chronic hepatitis) with a 10-40% risk of cirrhosis and an estimated 4% lifetime risk of hepatocellular carcinoma.
- the CDC estimates that each year in the United States there are 35,000 new cases of HCV infection and approximately ten thousand deaths attributed to HCV disease.
- the current standard of care is a pegylated interferon/ribavirin combination at a cost of approximately $31 ,000/year. These drugs have difficult dosing problems and side-effects that preclude their use in almost half of diagnosed patients. Pegylated interferon treatment is associated with menacing flu-like symptoms, irritability, inability to concentrate, suicidal ideation, and leukocytopenia. Ribavirin is associated with hemolytic anemia and birth defects.
- RNA virus diseases like HCV are few, and as described above are often associated with multiple adverse effects. While there are, in some cases, medicines available to reduce disease symptoms, there are few drugs to effectively inhibit replication of the underlying virus.
- RNA virus diseases including but not limited to chronic infection by the hepatitis C virus, and coupled with the limited availability and effectiveness of current antiviral pharmaceuticals, have created a compelling and continuing need for new pharmaceuticals to treat these diseases.
- the present invention describes novel pyridazinone compounds, pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, pharmaceutically acceptable salts, and pharmaceutically acceptable solvates thereof, which are useful in treating or preventing a hepatitis C virus infection in a patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a pyridazinone compound.
- the invention relates to compounds of Formula I
- R 1 and R 2 are independently H, alkyl, cycloalkyl, aryl, or heterocyclyl, and Ring A is 5 or 6- membered aryl or heterocyclyl, wherein the above alkyl, aryl, cycloalkyl, or heterocyclyl moieties are optionally substituted by 1-3 substituents selected from alkanoyl, alkylamine, amino, aryl, cycloalkyl, heterocyclyl,
- C 6 alkyl)S(O) 2 (C 1 -C 6 alkyl), -NHC(O)-(C 1 ⁇ C 6 alkyl)-S-(heterocyclyl), - NHS(O) 2 -(C 1 -C 6 alkyl), -NHS(O) 2 -(aryl), -NHS(0) 2 -(cycloalkyl), - NHS(O) 2 -(heterocyclyl), -NHS(O)(C 1 -C 6 alkyl), -NHS(O)(aryl), -
- the compound of the invention relates to compounds of Formula I wherein R 1 is selected from the group consisting of C 1 -C 6 alkyl, aryl, and heterocyclyl having 1 to 3 N, O, or S atoms.
- R 1 is selected from the group consisting of:
- the invention relates to compounds of the Formula I, wherein R 2 is selected from the group consisting OfC 1 -C 6 alkyl optionally substituted with C 6 -C 10 aryl or C 3 -C 8 cycloalkyl, and C 3 -C 9 heterocyclyl having 1 to 3 N, O, or S atoms and C 6 -C 10 aryl.
- the aryl, cycloalkyl and heterocyclyl are optionally further substituted with C 1 -C 6 alkyl or halo.
- R 2 is selected from the group consisting of:
- Ring A of Formula I is a 5- or 6-membered aryl or heterocyclyl, optionally substituted with alkyl, -halo, -OH, -O-alkyl, - OCHR 3 C(O)O-alkyl, -OCHR 3 C(O)NR 4 R 5 , -NHR 4 , -NR 4 C(O)-aryl, or -NO 2 , wherein R 3 , R 4 , and R 5 are independently -H or C 1 -C 6 alkyl, or R 4 and R 5 combine with the N atom to which they are attached to form a 5- or 6-membered heterocyclyl ring optionally substituted with -NH 2 .
- ring A together with the ring to which it is fused, is selected from the group consisting of:
- the invention relates to compounds of the Formula I selected from the group consisting of
- R 1 and R 2 are the same as defined immediately above, and R 6 is selected from the group consisting of:
- the invention relates to compounds of Formula I, where R 1 is selected from the group consisting of:
- the invention relates to compounds of Formula I, where R 2 is selected from the group consisting of:
- the invention relates to compounds of Formula I selected from the group consisting of:
- R 1 and R 2 are the same as defined immediately above, and R 7 is selected from the group consisting of:
- the compound of the invention is selected from the group consisting of:
- the invention relates to compounds of Formula I, where R 2 is selected from the group consisting of:
- the invention relates to compounds of Formula II:
- R 1 and R 2 are the same as defined immediately above, and R 7 is selected from the group consisting of:
- the invention is also directed to pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, pharmaceutically acceptable salts, and pharmaceutically acceptable solvates of the compounds, prodrugs, or metabolites of Formula I.
- Advantageous methods of making the compounds of Formula I are also described.
- the invention encompasses a method for treating or preventing hepatitis C virus infection in a mammal in need thereof, preferably in a human in need thereof, comprising administering to the patient a therapeutically or prophylactically effective amount of a Formula I compound.
- the invention encompasses a method for treating or preventing hepatitis C virus infection by administering to a patient in need thereof a therapeutically or prophylactically effective amount of a Formula I compound that is an inhibitor of HCV NS5B polymerase.
- the invention encompasses a method for treating or preventing hepatitis C virus infection in a patient in need thereof, comprising administering to the patient a therapeutically or prophylactically effective amount of a compound of Formula I and a pharmaceutically acceptable excipient, carrier, or vehicle.
- the invention encompasses a method for treating or preventing hepatitis C virus infection in a patient in need thereof, comprising administering to the patient a therapeutically or prophylactically effective amount of a compound of Formula I and an additional therapeutic agent, preferably an additional antiviral agent or an immunomodulatory agent.
- alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched, or cyclic moieties (including fused and bridged bicyclic and spirocyclic moieties), or a combination of the foregoing moieties.
- cyclic moieties including fused and bridged bicyclic and spirocyclic moieties, or a combination of the foregoing moieties.
- the group must have at least three carbon atoms.
- alkenyl as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above and including E and Z isomers of said alkenyl moiety.
- alkynyl as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above.
- alkoxy as used herein, unless otherwise indicated, includes O-alkyl groups wherein alkyl is as defined above.
- the term “Me” means methyl
- Et means ethyl
- Ac means acetyl.
- cycloalkyl refers to a non-aromatic, saturated or partially saturated, monocyclic or fused, spiro or unfused bicyclic or tricyclic hydrocarbon referred to herein containing a total of from 3 to 10 carbon atoms, preferably 5-8 ring carbon atoms.
- exemplary cycloalkyls include monocyclic rings having from 3-7, preferably 3-6, carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
- Illustrative examples of cycloalkyl are derived from, but not limited to, the following:
- aryl as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
- heterocyclic or “heterocyclyl”, as used herein, unless otherwise indicated, includes aromatic (e.g., heteroaryls) and non-aromatic heterocyclic groups containing one to four heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 4-10 atoms in its ring system, and with the proviso that the ring of said group does not contain two adjacent O atoms.
- Non-aromatic heterocyclic groups include groups having only 3 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system.
- the heterocyclic groups include benzo-fused ring systems.
- An example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine).
- An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl.
- non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl.
- aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinox
- the foregoing groups may be C-attached or N-attached where such is possible.
- a group derived from pyrrole maybe pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
- a group derived from imidazole maybe imidazol-1-yl (N-attached) or imidazol-3-yl (C- attached).
- the 4-10 membered heterocyclic may be optionally substituted on any ring carbon, sulfur, or nitrogen atom(s) by one to two oxo, per ring.
- heterocyclic group wherein 2 ring carbon atoms are substituted with oxo moieties is 1,1-dioxo-thiomo ⁇ holinyl.
- 4-10 membered heterocyclic are derived from, but not limited to, the following:
- immunomodulator refers to natural or synthetic products capable of modifying the normal or aberrant immune system through stimulation or suppression.
- preventing refers to the ability of a compound or composition of the invention to prevent a disease identified herein in patients diagnosed as having the disease or who are at risk of developing such disease.
- the term also encompasses preventing further progression of the disease in patients who are already suffering from or have symptoms of such disease.
- patient or subject means an animal (e.g., cow, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, guinea pig, etc.) or a mammal, including chimeric and transgenic animals and mammals, hi the treatment or prevention of HCV infection, the term “patient” or “subject” preferably means a monkey or a human, most preferably a human. In a specific embodiment the patient or subject is infected by or exposed to the hepatitis C virus.
- the patient is a human infant (age 0-2), child (age 2-17), adolescent (age 12-17), adult (age 18 and up) or geriatric (age 70 and up) patient, hi addition, the patient includes immunocompromised patients such as HIV positive patients, cancer patients, patients undergoing immunotherapy or chemotherapy. In a particular embodiment, the patient is a healthy individual, i.e., not displaying symptoms of other viral infections.
- a "therapeutically effective amount" refers to an amount of the compound of the invention sufficient to provide a benefit in the treatment or prevention of viral disease, to delay or minimize symptoms associated with viral infection or viral-induced disease, or to cure or ameliorate the disease or infection or cause thereof.
- a therapeutically effective amount means an amount sufficient to provide a therapeutic benefit in vivo.
- the term preferably encompasses a non-toxic amount that improves overall therapy, reduces or avoids symptoms or causes of disease, or enhances the therapeutic efficacy of or synergies with another therapeutic agent.
- the term a "prophylactically effective amount" refers to an amount of a compound of the invention or other active ingredient sufficient to result in the prevention of infection, recurrence or spread of viral infection.
- a prophylactically effective amount may refer to an amount sufficient to prevent initial infection or the recurrence or spread of the infection or a disease associated with the infection.
- the term preferably encompasses a non-toxic amount that improves overall prophylaxis or enhances the prophylactic efficacy of or synergies with another prophylactic or therapeutic agent.
- combination refers to the use of more than one prophylactic and/or therapeutic agents simultaneously or sequentially and in a manner that their respective effects are additive or synergistic.
- treating refers to:
- the compounds of the invention may exhibit the phenomenon of tautomerism. While Formula I cannot expressly depict all possible tautomeric forms, it is to be understood that Formula I is intended to represent any tautomeric form of the depicted compound and is not to be limited merely to a specific compound form depicted by the formula drawings. For illustration, and in no way limiting the range of tautomers, the compounds of Formula I may exist as the following:
- inventive compounds may exist as single stereoisomers (i.e., essentially free of other stereoisomers), racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates and mixtures thereof are intended to be within the scope of the present invention.
- inventive compounds that are optically active are used in optically pure form.
- an optically pure compound having one chiral center is one that consists essentially of one of the two possible enantiomers (i.e., is enantiomerically pure), and an optically pure compound having more than one chiral center is one that is both diastereomerically pure and enantiomerically pure.
- the compounds of the present invention are used in a form that is at least 90% optically pure, that is, a form that contains at least 90% of a single isomer (80% enantiomeric excess ("e.e.") or diastereomeric excess (“d.e.”)), more preferably at least 95% (90% e.e. or d.e.), even more preferably at least 97.5% (95% e.e. or d.e.), and most preferably at least 99% (98% e.e. or d.e.).
- Formula I is intended to cover solvated as well as unsolvated forms of the identified structures.
- Formula I includes compounds of the indicated structure in both hydrated and non-hydrated forms.
- Other examples of solvates include the structures in combination with isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
- the invention includes pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of such compounds and metabolites.
- a pharmaceutically acceptable prodrug is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt of such compound prior to exhibiting its pharmacological effect (s).
- the prodrug is formulated with the objective(s) of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased hydrosolubility), and/or decreased side effects (e.g., toxicity).
- the prodrug can be readily prepared from the compounds of Formula I using methods known in the art, such as those described by Burger's Medicinal Chemistry and Drug Chemistry, 1, 172-178, 949-982 (1995). See also Bertolini et al., J. Med.
- a pharmaceutically active metabolite is intended to mean a pharmacologically active product produced through metabolism in the body of a specified compound or salt thereof. After entry into the body, most drugs are substrates for chemical reactions that may change their physical properties and biologic effects. These metabolic conversions, which usually affect the polarity of the Formula I compounds, alter the way in which drugs are distributed in and excreted from the body. However, in some cases, metabolism of a drug is required for therapeutic effect. For example, anticancer drugs of the anti-metabolite class must be converted to their active forms after they have been transported into a cancer cell.
- a feature characteristic of many of these transformations is that the metabolic products, or "metabolites,” are more polar than the parent drugs, although a polar drug does sometime yield a less polar product.
- the specific secretory mechanisms for anions and cations in the proximal renal tubules and in the parenchymal liver cells operate upon highly polar substances.
- phenacetin (acetophenetidin) and acetanilide are both mild analgesic and antipyretic agents, but are transformed within the body to a more polar and more effective metabolite, p-hydroxyacetanilid (acetaminophen), which is widely used today.
- acetanilide When a dose of acetanilide is given to a person, the successive metabolites peak and decay in the plasma sequentially. During the first hour, acetanilide is the principal plasma component. In the second hour, as the acetanilide level falls, the metabolite acetaminophen concentration reaches a peak.
- the principal plasma component is a further metabolite that is inert and can be excreted from the body.
- the plasma concentrations of one or more metabolites, as well as the drug itself, can be pharmacologically important.
- a pharmaceutically acceptable salt is intended to mean a salt that retains the biological effectiveness of the free acids and bases of the specified compound and that is not biologically or otherwise undesirable.
- a compound of the invention may possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
- Exemplary pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an inorganic base, such as salts including sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4- dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinifrobenzoates, hydroxybenzoates, methoxybenzoates
- the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid , such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an ⁇ -hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like.
- an inorganic acid such as hydrochloric
- the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.
- suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
- the present invention provides methods for treating or preventing a hepatitis C virus infection in a patient in need thereof.
- the present invention further provides methods for introducing a therapeutically effective amount of the Formula I compound or combination of such compounds into the blood stream of a patient in the treatment and/or prevention of hepatitis C viral infections.
- the magnitude of a prophylactic or therapeutic dose of a Formula I compound of the invention or a pharmaceutically acceptable salt, solvate, or hydrate, thereof in the acute or chronic treatment or prevention of an infection will vary, however, with the nature and severity of the infection, and the route by which the active ingredient is administered.
- the dose, and in some cases the dose frequency will also vary according to the infection to be treated, the age, body weight, and response of the individual patient. Suitable dosing regimens can be readily selected by those skilled in the art with due consideration of such factors.
- the methods of the present invention are particularly well suited for human patients, hi particular, the methods and doses of the present invention can be useful for immunocompromised patients including, but not limited to cancer patients, HIV infected patients, and patients with an immunodegenerative disease. Furthermore, the methods can be useful for immunocompromised patients currently in a state of remission. The methods and doses of the present invention are also useful for patients undergoing other antiviral treatments. The prevention methods of the present invention are particularly useful for patients at risk of viral infection. These patients include, but are not limited to health care workers, e.g., doctors, nurses, hospice care givers; military personnel; teachers; childcare workers; patients traveling to, or living in, foreign locales, in particular third world locales including social aid workers, missionaries, and foreign diplomats.
- health care workers e.g., doctors, nurses, hospice care givers; military personnel; teachers; childcare workers; patients traveling to, or living in, foreign locales, in particular third world locales including social aid workers, missionaries, and foreign diplomats.
- the methods and compositions include the treatment of refractory patients or patients resistant to treatment such as resistance to reverse transcriptase inhibitors, protease inhibitors, etc.
- Doses Toxicity and efficacy of the compounds of the invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LO 50 IED 50 .
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage of the compounds for use in humans.
- the dosage of such compounds lie preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 5O O ' - ⁇ - , the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture; alternatively, the dose of the Formula I compound may be formulated in animal models to achieve a circulating plasma concentration range of the compound that corresponds to the concentration required to achieve a fixed magnitude of response. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
- the protocols and compositions of the invention are preferably tested in vitro, and then in vivo, for the desired therapeutic or prophylactic activity, prior to use in humans.
- in vitro assays which can be used to determine whether administration of a specific therapeutic protocol is indicated, include in vitro cell culture assays in which cells that are responsive to the effects of the Formula I compounds are exposed to the ligand and the magnitude of response is measured by an appropriate technique. The assessment of the Formula I compound is then evaluated with respect to the Formula I compound potency, and the degree of conversion of the Formula I compound prodrug.
- Compounds for use in methods of the invention can be tested in suitable animal model systems prior to testing in humans, including but not limited to in rats, mice, chicken, cows, monkeys, rabbits, hamsters, etc. The compounds can then be used in the appropriate clinical trials.
- I compound of the invention or a pharmaceutically acceptable salt, solvate, or hydrate thereof in the acute or chronic treatment or prevention of an infection or condition will vary with the nature and severity of the infection, and the route by which the active ingredient is administered.
- the dose, and perhaps the dose frequency will also vary according to the infection to be treated, the age, body weight, and response of the individual patient. Suitable dosing regimens can be readily selected by those skilled in the art with due consideration of such factors.
- the dose administered depends upon the specific compound to be used, and the weight and condition of the patient.
- the dose may differ for various particular Formula I compounds; suitable doses can be predicted on the basis of the aforementioned in vitro measurements and on the basis of animal studies, such that smaller doses will be suitable for those Formula I compounds that show effectiveness at lower concentrations than other Formula I compounds when measured in the systems described or referenced herein.
- the dose per day is in the range of from about 0.001 to 100 mg/kg, preferably about 1 to 25 mg/kg, more preferably about 5 to 15 mg/kg.
- about 0.1 mg to about 15 g per day is administered in about one to four divisions a day, preferably 100 mg to 12 g per day, more preferably from 100 mg to 8000 mg per day.
- the recommended daily dose ran can be administered in cycles as single agents or in combination with other therapeutic agents.
- the daily dose is administered in a single dose or in equally divided doses.
- the recommended daily dose can be administered once time per week, two times per week, three times per week, four times per week or five times per week.
- the compounds of the invention are administered to provide systemic distribution of the compound within the patient.
- the compounds of the invention are administered to produce a systemic effect in the body.
- the compounds of the invention are administered via oral, mucosal (including sublingual, buccal, rectal, nasal, or vaginal), parenteral (including subcutaneous, intramuscular, bolus injection, intraarterial, or intravenous), transdermal, or topical administration.
- the compounds of the invention are administered via mucosal (including sublingual, buccal, rectal, nasal, or vaginal), parenteral (including subcutaneous, intramuscular, bolus injection, intraarterial, or intravenous), transdermal, or topical administration.
- the compounds of the invention are administered via oral administration.
- the compounds of the invention are not administered via oral administration.
- Specific methods of the invention further comprise the administration of an additional therapeutic agent (i.e., a therapeutic agent other than a compound of the invention).
- an additional therapeutic agent i.e., a therapeutic agent other than a compound of the invention.
- the compounds of the invention can be used in combination with at least one other therapeutic agent.
- Therapeutic agents include, but are not limited to antibiotics, antiemetic agents, antidepressants, and antifungal agents, anti-inflammatory agents, antiviral agents, anticancer agents, immunomodulatory agents, ⁇ -interferons, /3-interferons, ribavirin, alkylating agents, hormones, cytokines, or toll receptor-like modulators.
- the invention encompasses the administration of an additional therapeutic agent that is HCV specific or demonstrates anti-HCV activity.
- the Formula I compounds of the invention can be administered or formulated in combination with antibiotics.
- they can be formulated with a macrolide (e.g., tobramycin (Tobi®)), a cephalosporin (e.g., cephalexin (Keflex®), cephradine (Velosef®), cefuroxime (Ceftin®), cefprozil (Cefzil®), cefaclor (Ceclor®), cefixime (Suprax®) or cefadroxil (Duricef®)), a clarithromycin (e.g., clarithromycin (Biaxin®)), an erythromycin (e.g., erythromycin (EMycin®)), a penicillin (e.g., penicillin V (V-Cillin K® or Pen Vee K®)) or a quinolone (e.g., ofloxacin (Floxin®), ciprofloxacin (Cipro®) or
- aminoglycoside antibiotics e.g., apramycin, arbekacin, bambermycins, butirosin, dibekacin, neomycin, neomycin, undecylenate, netihnicin, paromomycin, ribostamycin, sisomicin, and spectinomycin
- amphenicol antibiotics e.g., azidamfenicol, chloramphenicol, florfenicol, and thiamphenicol
- ansamycin antibiotics e.g., rifamide and rifampin
- carbacephems e.g., loracarbef
- carbapenems e.g., biapenem and imipenem
- cephalosporins e.g., cefaclor, cefadroxil, cefamandole, cefatrizine, cefazedone, cefozopran, cefpimi
- the Formula I compounds of the invention can also be administered or formulated in combination with an antiemetic agent.
- Suitable antiemetic agents include, but are not limited to, metoclopromide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acethylleucine monoethanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinols, thiethylperazine, thioproperazine, tropisetron, and mixture
- the Formula I compounds of the invention can be administered or formulated in combination with an antidepressant.
- Suitable antidepressants include, but are not limited to, binedaline, caroxazone, citalopram, dimethazan, fencamine, indalpine, indeloxazine hydrocholoride, nefopam, nomifensine, oxitriptan, oxypertine, paroxetine, sertraline, thiazesim, trazodone, benmoxine, iproclozide, iproniazid, isocarboxazid, nialamide, octamoxin, phenelzine, cotinine, rolicyprine, rolipram, maprotiline, metralindole, mianserin, mirtazepine, adinazolam, amitriptyline, amitriptylinoxide, amoxapine, butripty
- the Formula I compound s of the invention can be administered or formulated in combination with an antifungal agent.
- Suitable antifungal agents include but are not limited to amphotericin B, itraconazole, ketoconazole, fluconazole, intrathecal, flucytosine, miconazole, butoconazole, clotrimazole, nystatin, terconazole, tioconazole, ciclopirox, econazole, haloprogrin, naftif ⁇ ne, terbinafine, undecylenate, and griseofulvin.
- the Formula I compounds of the invention can be administered or formulated in combination with an anti-inflammatory agent.
- Useful anti-inflammatory agents include, but are not limited to, non-steroidal anti-inflammatory drugs such as salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbinprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, nabumetome, phenylbutazone, oxyphenbutazone, anti
- Formula I compounds of the invention can be administered or formulated in combination with another antiviral agent.
- Useful antiviral agents include, but are not limited to, protease inhibitors, nucleoside reverse transcriptase inhibitors, non- nucleoside reverse transcriptase inhibitors and nucleoside analogs.
- the antiviral agents include but are not limited to zidovudine, acyclovir, gangcyclovir, vidarabine, idoxuridine, trifluridine, levovirin, viramidine and ribavirin, as well as foscarnet, amantadine, rimantadine, saquinavir, indinavir, amprenavir, lopinavir, ritonavir, the a- interferons; /3-interferons; adefovir, clevadine, entecavir, pleconaril.
- the Formula I compound of the invention can be administered or formulated in combination with an immunomodulatory agent.
- Immunomodulatory agents include, but are not limited to, methothrexate, leflunomide, cyclophosphamide, cyclosporine A, mycophenolate mofetil, rapamycin (sirolimus), mizoribine, deoxyspergualin, brequinar, malononitriloamindes ⁇ e.g., leflunamide), T cell receptor modulators, and cytokine receptor modulators, peptide mimetics, and antibodies ⁇ e.g., human, humanized, chimeric, monoclonal, polyclonal, Fvs, ScFvs, Fab or F(ab)2 fragments or epitope binding fragments), nucleic acid molecules ⁇ e.g., antisense nucleic acid molecules and triple helices), small molecules, organic compounds, and inorganic compounds.
- T cell receptor modulators include, but are not limited to, anti-T cell receptor antibodies (e.g., anti-CD4 antibodies (e.g., cM-T412 (Boehringer), IDEC-CE9.1® (IDEC and SKB), mAB 4162W94, Orthoclone and OKTcdr4a (Janssen-Cilag)), anti-CD3 antibodies (e.g., Nuvion (Product Design).
- anti-T cell receptor antibodies e.g., anti-CD4 antibodies (e.g., cM-T412 (Boehringer), IDEC-CE9.1® (IDEC and SKB), mAB 4162W94, Orthoclone and OKTcdr4a (Janssen-Cilag)
- anti-CD3 antibodies e.g., Nuvion (Product Design
- anti-CD5 antibodies e.g., an anti-CD5 ricin-linked immunoconjugate
- anti-CD7 antibodies e.g., CHH-380 (Novartis)
- anti-CD8 antibodies anti-CD40 ligand monoclonal antibodies
- anti-CD52 antibodies e.g., CAMPATH IH (Ilex)
- anti-CD2 antibodies e.g., Xanelim (Genentech)
- anti-B7 antibodies e.g., IDEC-114 (IDEC)
- TLR toll receptor-like
- cytokine receptor modulators include, but are not limited to, soluble cytokine receptors (e.g., the extracellular domain of a TNF-ce receptor or a fragment thereof, the extracellular domain of an IL- 1/3 receptor or a fragment thereof, and the extracellular domain of an IL-6 receptor or a fragment thereof), cytokines or fragments thereof (e.g., interleukin (IL)-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL- 10, H-Il, IL-12, IL-15, TNF- ⁇ , interferon (IFN)-O!, IFN-/3, IFN-7, and GM-CSF), anti-cytokine receptor antibodies (e.g., anti-IFN receptor antibodies, anti-IL-2 receptor antibodies (e.g., Zenapax (Protein Design Labs)), anti-IL-4 receptor antibodies, anti-IL-6 receptor antibodies, anti-IL-10 receptor antibodies, and anti-IL- 12 receptor
- the Formula I compounds of the invention can be administered or formulated in combination with an agent which inhibits viral enzymes, including but not limited to inhibitors of HCV protease, such as BILN 2061 and inhibitors of NS5b polymerase such as NMl 07 and its prodrug NM283 (Idenix Pharmaceuticals, Inc., Cambridge, MA).
- an agent which inhibits viral enzymes including but not limited to inhibitors of HCV protease, such as BILN 2061 and inhibitors of NS5b polymerase such as NMl 07 and its prodrug NM283 (Idenix Pharmaceuticals, Inc., Cambridge, MA).
- the Formula I compounds of the invention can be administered or formulated in combination with an agent which inhibits HCV polymerase such as those described in Wu, CurrDrug Targets Infect Disord. 2003;3(3):207-19 or in combination with compounds that inhibit the helicase function of the virus such as those described in BretnerM, et al Nucleosides Nucleotides Nucleic Acids. 2003;22(5-8):1531, or with inhibitors of other HCV specific targets such as those described in Zhang X., IDrugs, 5(2), 154-8 (2002).
- an agent which inhibits HCV polymerase such as those described in Wu, CurrDrug Targets Infect Disord. 2003;3(3):207-19 or in combination with compounds that inhibit the helicase function of the virus such as those described in BretnerM, et al Nucleosides Nucleotides Nucleic Acids. 2003;22(5-8):1531, or with inhibitors of other HCV specific targets such as those described in Zhang X., IDrugs, 5
- the Formula I compounds of the invention can be administered or formulated in combination with an agent which inhibits viral replication.
- the Formula I compounds of the invention can be administered or formulated in combination with cytokines.
- cytokines include, but are not limited to, interleukm-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-9 (IL-9), interleukin-10 (IL-10), interleukin-12 (IL- 12), interleukin 15 (IL- 15), interleukin 18 (IL-18), platelet derived growth factor (PDGF), erythropoietin (Epo), epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte macrophage stimulating factor (GM- CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), prolactin, and interfer
- the Formula I compounds of the invention can be administered or formulated in combination with hormones.
- hormones include, but are not limited to, luteinizing hormone releasing hormone (LHRH), growth hormone (GH), growth hormone releasing hormone, ACTH, somatostatin, somatotropin, somatomedin, parathyroid hormone, hypothalamic releasing factors, insulin, glucagon, enkephalins, vasopressin, calcitonin, heparin, low molecular weight heparins, heparinoids, synthetic and natural opioids, insulin thyroid stimulating hormones, and endorphins.
- LHRH luteinizing hormone releasing hormone
- GH growth hormone
- ACTH ACTH
- somatostatin somatotropin
- somatomedin parathyroid hormone
- hypothalamic releasing factors insulin
- glucagon enkephalins
- vasopressin vasopressin
- calcitonin heparin, low molecular weight
- Formula I compounds of the invention can be administered or formulated in combination with /3-interferons which include, but are not limited to, interferon ⁇ - Ia, interferon ⁇ - Ib.
- Formula I compounds of the invention can be administered or formulated in combination with ⁇ -interferons which include, but are not limited to, interferon a-l, interferon ⁇ -2a (roferon), interferon ⁇ -2b, intron, Peg-Intron, Pegasys, consensus interferon (infergen) and albuferon.
- ⁇ -interferons include, but are not limited to, interferon a-l, interferon ⁇ -2a (roferon), interferon ⁇ -2b, intron, Peg-Intron, Pegasys, consensus interferon (infergen) and albuferon.
- the Formula I compounds of the invention can be administered or formulated in combination with an absorption enhancer, particularly those which target the lymphatic system, including, but not limited to sodium glycocholate; sodium caprate; N-lauryl-
- Other known absorption enhancers can also be used.
- the invention also encompasses a pharmaceutical composition comprising one or more Formula I compounds of the invention and one or more absorption enhancers.
- the Formula I compounds of the invention can be administered or formulated in combination with an alkylating agent.
- alkylating agents include, but are not limited to nitrogen mustards, ethylenimines, methylmelamines, alkyl sulfonates, nitrosoureas, triazenes, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, hexamethylmelaine, thiotepa, busulfan, carmustine, streptozocin, dacarbazine and temozolomide.
- the compounds of the invention and the other therapeutics agent can act additively or, more preferably, synergistically.
- a composition comprising a compound of the invention is administered concurrently with the administration of another therapeutic agent, which can be part of the same composition or in a different composition from that comprising the compounds of the invention.
- a compound of the invention is administered prior to or subsequent to administration of another therapeutic agent, hi a separate embodiment, a compound of the invention is administered to a patient who has not previously undergone or is not currently undergoing treatment with another therapeutic agent, particularly an antiviral agent.
- the methods of the invention comprise the administration of one or more Formula I compounds of the invention without an additional therapeutic agent.
- compositions and single unit dosage forms comprising a Formula I compound of the invention, or a pharmaceutically acceptable salt, or hydrate thereof, are also encompassed by the invention.
- Individual dosage forms of the invention may be suitable for oral, mucosal (including sublingual, buccal, rectal, nasal, or vaginal), parenteral (including subcutaneous, intramuscular, bolus injection, intraarterial, or intravenous), transdermal, or topical administration.
- Pharmaceutical compositions and dosage forms of the invention typically also comprise one or more pharmaceutically acceptable excipients. Sterile dosage forms are also contemplated.
- pharmaceutical composition encompassed by this embodiment includes a Formula I compound of the invention, or a pharmaceutically acceptable salt, or hydrate thereof, and at least one additional therapeutic agent. Examples of additional therapeutic agents include, but are not limited to, those listed above.
- composition, shape, and type of dosage forms of the invention will typically vary depending on their use.
- a dosage form used in the acute treatment of a disease or a related disease may contain larger amounts of one or more of the active ingredients it comprises than a dosage form used in the chronic treatment of the same disease.
- a parenteral dosage form may contain smaller amounts of one or more of the active ingredients it comprises than an oral dosage form used to treat the same disease or disorder.
- dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
- suspensions e.g., aqueous
- Typical pharmaceutical compositions and dosage forms comprise one or more carriers, excipients or diluents.
- Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient.
- oral dosage forms such as tablets may contain excipients not suited for use in parenteral dosage forms. The suitability of a particular excipient may also depend on the specific active ingredients in the dosage form.
- This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising active ingredients, since water can facilitate the degradation of some compounds.
- water can facilitate the degradation of some compounds.
- water e.g., 5%
- water is widely accepted in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. See, e.g., Carstensen, Drug Stability: Principles & Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-80.
- water and heat accelerate the decomposition of some compounds.
- the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.
- Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
- anhydrous pharmaceutical composition should be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e.g., vials), blister packs, and strip packs.
- compositions and dosage forms that comprise one or more compounds that reduce the rate by which an active ingredient will decompose.
- Such compounds which are referred to herein as
- antioxidants include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers.
- compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups). Such dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington 's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
- Typical oral dosage forms of the invention are prepared by combining the active ingredient(s) in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques.
- Excipients can take a wide variety of forms depending on the form of preparation desired for administration.
- excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
- excipients suitable for use in solid oral dosage forms include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents.
- tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid excipients are employed. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Such dosage forms can be prepared by any of the methods of pharmacy. In general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.
- a tablet can be prepared by compression or molding.
- Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with an excipient.
- Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants.
- Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives ⁇ e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, ⁇ e.g., Nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.
- fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
- the binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.
- Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH-101, AVICEL-PH-103 AVICEL RC-581, AVICEL- PH- 105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, PA), and mixtures thereof.
- a specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose sold as AVICEL RC- 581.
- Suitable anhydrous or low moisture excipients or additives include AVICEL- PH-103TM and Starch 1500 LM.
- Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions. Thus, a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention.
- the amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
- Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, specifically from about 1 to about 5 weight percent of disintegrant.
- Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
- Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof.
- calcium stearate e.g., magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc
- hydrogenated vegetable oil e.g., peanut oil, cottonseed oil
- Additional lubricants include, for example, a syloid silica gel (AEROSIL 200, manufactured by W.R. Grace Co. of Baltimore, MD), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Piano, TX), CAB-O-SIL (apyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA), and mixtures thereof. If used at all, lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated. Delayed Release Dosage Forms
- Active ingredients of the invention can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,566, each of which is incorporated herein by reference.
- Such dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
- Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention.
- the invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-release.
- AU controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts.
- the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time.
- Advantages of controlled-release formulations include extended activity of the drag, reduced dosage frequency, and increased patient compliance.
- controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and can thus affect the occurrence of side (e.g., adverse) effects.
- Controlled-release formulations are designed to initially release an amount of drag (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drag to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drag must be released from the dosage form at a rate that will replace the amount of drag being metabolized and excreted from the body.
- Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.
- Parenteral Dosage Forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial.
- parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient.
- parenteral dosage forms include, but are not limited to, solutions ready for injection, dry and/or lyophylized products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection (reconstitutable powders), suspensions ready for injection, and emulsions.
- Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
- water for Injection USP Water for Injection USP
- aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride
- Transdermal dosage forms include "reservoir type” or “matrix type” patches, which can be applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of active ingredients.
- Suitable excipients e.g., carriers and diluents
- other materials that can be used to provide transdermal and topical dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied.
- typical excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-l,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof.
- additional components may be used prior to, in conjunction with, or subsequent to treatment with active ingredients of the invention.
- penetration enhancers can be used to assist in delivering the active ingredients to the tissue.
- Suitable penetration enhancers include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).
- the pH of a pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied may also be adjusted to improve delivery of one or more active ingredients.
- the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.
- Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery.
- stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.
- Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
- Topical dosage forms of the invention include, but are not limited to, creams, lotions, ointments, gels, solutions, emulsions, suspensions, or other forms known to one of skill in the art. See, e.g., Remington 's Pharmaceutical Sciences, 18th eds., Mack Publishing, Easton PA (1990); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985).
- Suitable excipients e.g., carriers and diluents
- other materials that can be used to provide transdermal and topical dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied.
- typical excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane- 1,3-dioL isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof.
- penetration enhancers can be used to assist in delivering the active ingredients to the tissue.
- Suitable penetration enhancers include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).
- Tween 80 polysorbate 80
- Span 60 sorbitan monostearate
- Mucosal dosage forms of the invention include, but are not limited to, ophthalmic solutions, sprays and aerosols, or other forms known to one of skill in the art. See, e.g., Remington 's Pharmaceutical Sciences, 18th eds., Mack Publishing, Easton PA (1990); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985). Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels.
- the aerosol comprises a carrier.
- the aerosol is carrier free.
- the Formula I compounds of the invention may also be administered directly to the lung by inhalation.
- a Formula I compound can be conveniently delivered to the lung by a number of different devices.
- a Metered Dose Inhaler which utilizes canisters that contain a suitable low boiling propellant, e.g. , dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas can be used to deliver a Formula I compound directly to the lung.
- MDI devices are available from a number of suppliers such as 3M Corporation, Aventis, Boehringer Ingleheim, Forest Laboratories, Glaxo-Wellcome, Schering Plough and Vectura.
- a Dry Powder Inhaler (DPI) device can be used to administer a Formula I compound to the lung (see, e.g., Raleigh et al., Proc. Amer. Assoc. Cancer Research Annual Meeting, 1999, 40, 397, which is herein incorporated by reference).
- DPI devices typically use a mechanism such as a burst of gas to create a cloud of dry powder inside a container, which can then be inhaled by the patient.
- DPI devices are also well known in the art and can be purchased from a number of vendors which include, for example, Fisons, Glaxo-Wellcome, Inhale Therapeutic Systems, ML Laboratories, Qdose and Vectura.
- MDDPI multiple dose DPI
- a liquid spray device supplied, for example, by Aradigm Corporation. Liquid spray systems use extremely small nozzle holes to aerosolize liquid drug formulations that can then be directly inhaled into the lung.
- a nebulizer device is used to deliver a Formula I compound to the lung.
- Nebulizers create aerosols from liquid drug formulations by using, for example, ultrasonic energy to form fine particles that can be readily inhaled (See e.g., Verschoyle et al., British J. Cancer, 1999, 80, Suppl 2, 96, which is herein incorporated by reference).
- Examples of nebulizers include devices supplied by Sheffield/Systemic Pulmonary Delivery Ltd. (See, Armer et al., U.S. Pat. No. 5,954,047; van der Linden et al, U.S. Pat. No. 5,950,619; van der Linden et al., U.S. Pat. No.
- an electrohydrodynamic (“EHD”) aerosol device is used to deliver Formula I compounds to the lung.
- EHD aerosol devices use electrical energy to aerosolize liquid drug solutions or suspensions (see, e.g., Noakes et al., U.S. Pat. No. 4,765,539; Coffee, U.S. Pat.
- the electrochemical properties of the Formula I compounds formulation may be important parameters to optimize when delivering this drug to the lung with an EHD aerosol device and such optimization is routinely performed by one of skill in the art.
- EHD aerosol devices may more efficiently delivery drugs to the lung than existing pulmonary delivery technologies.
- Other methods of intra-pulmonary delivery of Formula I compounds will be known to the skilled artisan and are within the scope of the invention.
- Liquid drug formulations suitable for use with nebulizers and liquid spray devices and EHD aerosol devices will typically include a Formula I compound with a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier is a liquid such as alcohol, water, polyethylene glycol or a perfluorocarbon.
- another material may be added to alter the aerosol properties of the solution or suspension of the Formula I compound.
- this material is liquid such as an alcohol, glycol, polyglycol or a fatty acid.
- Other methods of formulating liquid drug solutions or suspension suitable for use in aerosol devices are known to those of skill in the art (see, e.g., Biesalski, U.S. Pat. Nos.
- a Formula I compound can also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- a Formula I compound can also be formulated as a depot preparation.
- Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- suitable polymeric or hydrophobic materials for example, as an emulsion in an acceptable oil
- ion exchange resins for example, as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- other pharmaceutical delivery systems can be employed.
- Liposomes and emulsions are well known examples of delivery vehicles that can be used to deliver Formula I compounds.
- Certain organic solvents such as dimethylsulfoxide can also be employed, although usually at the cost of greater toxicity.
- a Formula I compound can also be delivered in a controlled release system.
- a pump can be used (Sefton, CRC Crit. RefBiomed Eng., 1987, 14, 201; Buchwald et al, Surgery, 1980, 88, 507; Saudek et al, N. Engl. J. Med., 1989, 321, 574).
- polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, FIa.
- a controlled-release system can be placed in proximity of the target of the compounds of the invention, e.g., the lung, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115 (1984)).
- Other controlled-release system can be used (see, e.g. Langer, Science, 1990, 249, 1527).
- Suitable excipients e.g., carriers and diluents
- other materials that can be used to provide mucosal dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular site or method which a given pharmaceutical composition or dosage form will be administered.
- typical excipients include, but are not limited to, water, ethanol, ethylene glycol, propylene glycol, butane- 1, 3 -diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof, which are non-toxic and pharmaceutically acceptable. Examples of such additional ingredients are well known in the art.
- a pharmaceutical composition or dosage form or of the tissue to which the pharmaceutical composition or dosage form is applied, can also be adjusted to improve delivery of one or more active ingredients.
- the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.
- Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery.
- stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.
- Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
- the invention provides a pharmaceutical pack or kit comprising one or more containers comprising a Formula I compound useful for the treatment or prevention of a Hepatitis C virus infection.
- the invention provides a pharmaceutical pack or kit comprising one or more containers comprising a Formula I compound useful for the treatment or prevention of a Hepatitis C virus infection and one or more containers comprising an additional therapeutic agent, including but not limited to those listed above, in particular an antiviral agent, an interferon, an agent which inhibits viral enzymes, or an agent which inhibits viral replication, preferably the additional therapeutic agent is HCV specific or demonstrates anti-HCV activity.
- the invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the pharmaceutical compositions of the invention.
- Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- inventive agents may be prepared using the reaction routes and synthesis schemes as described below, employing the general techniques known in the art using starting materials that are readily available.
- the synthesis of non-exemplified compounds according to the invention may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions.
- other reactions disclosed herein or generally known in the art will be recognized as having applicability for preparing other compounds of the invention.
- NMR spectra and 13 C-NMR were recorded on a Varian Mercury- VX400 instrument operating at 400 MHz.
- NMR spectra were obtained as CDCl 3 solutions (reported in ppm), using chloroform as the reference standard (7.27 ppm for the proton and 77.00 ppm for carbon), CD 3 OD (3.4 and 4.8 ppm for the protons and 49.3 ppm for carbon), DMSO-d 6 (2.49 ppm for proton), or internally tetramethylsilane (0.00 ppm) when appropriate.
- Other NMR solvents were used as needed.
- Scheme 1 provides a general procedure that was used to prepare compounds of Formula I.
- ⁇ -keto-ester 1 can be treated with hydrazine 2 to form hydrazone 3.
- hydrazine 2 can be treated with hydrazine 2 to form hydrazone 3.
- Example 1-1 Scheme Ia describes the synthesis of compound 5a.
- ⁇ -keto-ester Ia (2.02 g, 12.3 mmol) was mixed with n-butylhydrazine oxalate (2a) (3.3 g, 18.5 mmol), CH 3 CO 2 Na (1.5 g, 18.5 mmol) and 40 mL of MeOH. The mixture was heated to reflux for 1.5 hours. LC-MS analysis of the reaction mixture confirmed the completion of the reaction. The inorganic solid was filtered off and washed with MeOH (20 mL x 2). The filtrate was concentrated under reduced vacuum. The liquid-liquid extraction was then performed using EtOAc (30 mL x 3) and H 2 O (20 mL).
- ⁇ -keto-ester 1 is treated with tert-butyl carbazate (6) in the presence of acetic acid under reflux in EtOH to give hydrazone 7.
- ⁇ -keto-ester (Ib) (1.0 g, 5.61 mmol) was mixed with tert-butyl carbazate (6) (742 mg, 5.61 mmol), 150 ⁇ L of acetic acid and 15 mL of EtOH. The mixture was heated at 60 °C for 3 hours. The LC-MS result confirmed the completion of the reaction and the product (7a) contains the both isomers of E- and Z-form. Upon standing at room temperature, white crystals precipitated from the solution. The top solution was decanted out and the remaining crystals were dried under reduced pressure to give the pure desired product (7a) which was directly used in the next step.
- Example 2-2 Scheme 2b describes the synthesis of compound 5c & 5d.
- compound 9b was made in the same way as that of compound 9a.
- Compound 9b (654.2 mg) was mixed with compound 4a (533.8 mg) and heated at 160 °C without solvent under N 2 atmosphere for Ih followed by heating at 185 °C for 3 h.
- hydrazone 3 can be treated with carboxylic acid 10 or with in-situ activated 10 by adding activating reagents such as HBTU, HATU, DCC or via acid chloride intermediate or other amide coupling methods known in the art to form key intermediate 11.
- activating reagents such as HBTU, HATU, DCC or via acid chloride intermediate or other amide coupling methods known in the art to form key intermediate 11.
- activating reagents such as HBTU, HATU, DCC or via acid chloride intermediate or other amide coupling methods known in the art to form key intermediate 11.
- activating reagents such as HBTU, HATU, DCC or via acid chloride intermediate or other amide coupling methods known in the art to form key intermediate 11.
- Compound 11 can be transformed to the title compound 5 via intra-molecular cyclization using base such as, but not limited to, NaOEt, KO'Bu, KOH, NaH, or LDA.
- Example 3-1 Scheme 3a describes the synthesis of compounds of 5e, 5f and 5g.
- the mixture was heated to reflux for 3.5 hours under N 2 atmosphere with stirring.
- reaction mixture was poured onto ice (10 mL), extracted with CHCl 3 (20 mL x 3). The organic layer was dried over MgSO 4 , filtered, concentrated under reduced pressure and further purified by flash chromatography on silica gel to give the desired product (5f) (42.2 mg) in 78.0 % yield.
- Example 3-2 Scheme 3b describes the synthesis of compounds of 5j and 5k.
- the reaction mixture was stirred 15 min at ambient temperature, filtered using a syringe filter with 0.2 ⁇ m PTFE membrane, and concentrated in vacuo.
- the crude mixture was purified by flash column chromatography using silica gel eluted with 0-3 % MeOH / CH 2 Cl 2 to give 5j (0.072 g, 77 %) as a red solid.
- Aniline (5j) can be easily derivatized to form sulfonamide by reacting compound 5j with sulfonyl chloride. It also can be alkylated by reacting with activated alkyl bromide or chloride. In addition, aniline 5j can be reacted with aldehydes via reductive amination to form secondary anilines using the methods known in the art.
- Example 4-1 Scheme 4a describes the synthesis of 4-(l,l-Dioxo-l,2-dihydro-l ⁇ 6 - pyrido[4,3-e][l,2,4]thiadiazin-3-yl)-5-hydroxy-2-(3-methyl-butyl)-6-thiophen-2-yl- 2H-pyridazin-3-one (51).
- Scheme 4a describes the synthesis of 4-(l,l-Dioxo-l,2-dihydro-l ⁇ 6 - pyrido[4,3-e][l,2,4]thiadiazin-3-yl)-5-hydroxy-2-(3-methyl-butyl)-6-thiophen-2-yl- 2H-pyridazin-3-one (51).
- the compound 13 was mixed with compound 14 and heated at a temperature between 160 0 C and 170 °C without solvent to give the amide 15.
- the compound 15 was then treated with 1, 8-diazabicyclo[5,4,0] undec-7-ene (DBU) in the presence of pyridine under heating condition in a sealed tube at a temperature between 140 °C to 160 °C to give the desired product (5).
- DBU 1, 8-diazabicyclo[5,4,0] undec-7-ene
- Example 5-1 Scheme 5a describes the synthesis of compound 5m.
- the ester (13a) made by Method 4 (86 mg, 0.26 mmol) and 3-Amino-5- chloro-thiophene-2-sulfonic acid amide (14b) (54 mg, 0.26 mmol) were mixed in a reaction vial and stirred in a preheated oil-bath at 160 °C for 10 mins to give the corresponding 5-hydroxy-2-(3-methyl-butyl)-3-oxo-6-thiophen-2-yl-2,3-dihydro- pyridazine-4-carboxylic acid (5-chloro-2-sulfamoyl-thiophen-3-yl)-amide (15a) as a dark yellow solid which was used directly in next step without further purification.
- Schemes 6-11 describe the synthetic routes for the indicated intermediates.
- Scheme 6 describes the synthesis of the intermediate 2.
- bromide 8 can react with tert-butyl carbazate 6 in the presence OfK 2 CO 3 upon heating to form Boc-protected hydrazine 1 using the literature procedures described in Huck et ah, Synlett, 2001 (9), 1467-1469 (2001) and Tetrahedron Letters, 40(18), 3543-3546 (1999).
- the Boc-group can be removed either by treating with TFA or HCl to give the hydrazine 2 as TFA or HCl salt.
- Example 6-1 Scheme 6a describes the synthesis of cyclobutylmethyl-hydrazine trifluoroacetic acid salt.
- the bromide 8b (2.39 g, 18.1 mmol) was reacted with fert-butyl carbazate 6 (3.24 g, 21.74 mmol) in the presence OfCs 2 CO 3 (12 g, 36.24 mmol) in 40 mL of DMF at 80 °C overnight.
- MS spectrum confirmed the formation of the desired product (Ia) with very little starting material left.
- the solid was filtered off. The filtrate was concentrated under vacuum and the crude residue was further purified by flash chromatography on silica gel using a gradient of ethyl acetate in hexane (0-50 %).
- Bromide 8 can be treated with large excess of hydrazine monohydrate in ethanol under reflux condition to give the desired hydrazine 2.
- Example 7-1 Scheme 7a describes the synthesis of 3-methyl-butyl-hydrazine (2).
- Scheme 8 describes the synthesis of the hydrazine oxalate salt 6.
- aldehyde 2 can undergo the reductive animation with compound 3_to give compound 4 which can be reduced to the compound 5.
- Compound 5 can be treated with NaOH followed by the acidification using oxalic acid to give the desired hydrazine oxalate salt (6).
- Example 8-1 Scheme 8a describes the synthesis of 2-cyclopropylethyl-hydrazine oxalate salt (6a).
- Oxalyl chloride (4.7 mL, 54.3 mmol) was dissolved in 120 mL Of CH 2 Cl 2 and the resulting solution cooled to -78 °C.
- Dimethylsulfoxide (7.7 mL, 0.109 mol) was added dropwise and the reaction mixture was stirred for 10 min at -78 0 C. 2-
- Cyclopropylethanol (7) (4.25g, 49.3 mmol) was dissolved in 10 mL OfCH 2 Cl 2 and added all at once to the reaction. After stirring for 1 h, triethylamine (34.7 mL, 0.25 mol) was added and the reaction was warmed to room temperature. The heterogeneous mixture was then partitioned between CH 2 Cl 2 and water and extracted twice with CH 2 Cl 2 . The organic layers were combined, washed with brine, dried over MgSO 4 , and filtered. The resulting solution of 2-cyclopropylethanal was concentrated in vacuo to a volume of approximately 50 mL using a rotary evaporator bath filled with crushed ice.
- N'-(2-cyclopropylethylidene)hydrazinecarboxylic acid ethyl ester (4a) (1.5 g, 8.9 mmol) was dissolved in 35 mL EtOH and to this solution was added 5% Pt/C (0.2 g, 0.9 mol). The atmosphere in the flask was evacuated and replaced three times with H 2 . The reaction was stirred at room temperature for 12 h under a slightly positive pressure of H 2 , upon which it was filtered through neutral alumina and concentrated to afford 1.4 g (93%) of the desired product (5a) as a clear colorless liquid.
- 2-Cvclopropylethyl-hvdrazine oxalate salt (6a): iV'-(2-Cyclopropylethyl)hydrazinecarboxylic acid ethyl ester (5a) (2.2 g, 12.6 mmol) was suspended in 7 mL of a 40 % aqueous NaOH solution. The biphasic mixture was heated for 12 h at 120 0 C, upon which it was cooled to room temperature and partitioned between brine and CH 2 Cl 2 . The organic layer was removed, dried over MgSO 4 , and filtered.
- Example 8-2 Synthesis of 3-methylbutyl hydrazine oxalate salt (6b).
- Scheme 9 describes the synthesis of intermediates of 9, 4a, 10a, 10b and 4b.
- a solution of 8 (15 g, 65.7 mmol) was dissolved in 140 mL of 50 % aqueous sulfuric acid. The solution was then heated to 130 0 C for 6 hours. The solution was then poured over ice and neutralized at 0 0 C with the addition of saturated aqueous sodium hydroxide. The mixture was then extracted with ethyl acetate. The organic phase was washed with brine, and dried over magnesium sulfate, filtered and dried in vacuo to produce 8.1 g of the desired product (9) as a brown solid in 60 % yield. See procedure described in Girard, Y, et ah, J. Chem. Soc. Perkin Trans 1, 1043-1047 (1979).
- Scheme 11 describes the synthesis of the intermediate 14b.
- Test results (IC 50 values) for compounds of Formula I are summarized in Table 1, wherein ++ means NS5B polymerase inhibition with IC 50 values less than 10 ⁇ M, + means IC 50 values between 10 ⁇ M and 50 ⁇ M and not determined means the IC50 value was not measured.
- the measured mass for each compound in Table 1 corresponded to the predicted mass.
- Human hepatocyte Huh7 cells containing the HCV dicistronic replicon were obtained from RaIf Bartenschlager at the University of Mainz, Germany . These cells are maintained under G418-Geneticin selection and passaged when 80-90% confluent. This Huh7 cell line contains an autonomously replicating RNA element
- the assay is conducted by preparing sufficient 96-well plates containing Huh7 cells, wherein cells are seeded at 4500 cells/well, in 200 ⁇ l of final media volume. Cells are then incubated for 24 hours at 37 0 C, 5% CO 2 , and 95% humidity before compound is added.
- Eight point half-log concentration response assays are conducted to determine potency/ECso of Formula I compounds to inhibit HCV replicon replication.
- the final percent DMSO acceptable in this assay system is 0.5 %.
- Compounds are diluted in media in an appropriate format and 50 ⁇ of each drug dilution is added to each well. Cells are then incubated with compounds for 3 days at 37 0 C, 5% CO 2 , and 95% humidity.
- RNA Quantification of RNA is performed by bDNA (branched DNA) technology from genospectra using NS3 as a RNA viral marker and GAPDH as a cellular RNA marker. Cell cytotoxicity is gauged by GAPDH level.
- bDNA branched DNA
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002589527A CA2589527A1 (en) | 2004-12-17 | 2005-12-16 | Pyridazinone compounds |
JP2007546930A JP2008526687A (en) | 2004-12-17 | 2005-12-16 | Pyridazinone compounds |
MX2007007264A MX2007007264A (en) | 2004-12-17 | 2005-12-16 | Pyridazinone compounds. |
AP2007004040A AP2007004040A0 (en) | 2004-12-17 | 2005-12-16 | Pyridazinone compounds |
EP05854333A EP1824847A2 (en) | 2004-12-17 | 2005-12-16 | Pyridazinone compounds |
AU2005316396A AU2005316396A1 (en) | 2004-12-17 | 2005-12-16 | Pyridazinone compounds |
EA200701297A EA200701297A1 (en) | 2004-12-17 | 2005-12-16 | COMPOUNDS OF PYRIDAZINON |
IL183510A IL183510A0 (en) | 2004-12-17 | 2007-05-29 | Pyridazinone compounds |
NO20073105A NO20073105L (en) | 2004-12-17 | 2007-06-18 | pyridazinone |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63661604P | 2004-12-17 | 2004-12-17 | |
US60/636,616 | 2004-12-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006066079A2 true WO2006066079A2 (en) | 2006-06-22 |
WO2006066079A3 WO2006066079A3 (en) | 2006-12-14 |
Family
ID=36588590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/045588 WO2006066079A2 (en) | 2004-12-17 | 2005-12-16 | Pyridazinone compounds |
Country Status (21)
Country | Link |
---|---|
US (1) | US7425552B2 (en) |
EP (1) | EP1824847A2 (en) |
JP (1) | JP2008526687A (en) |
KR (1) | KR20070100743A (en) |
CN (1) | CN101137651A (en) |
AP (1) | AP2007004040A0 (en) |
AR (1) | AR054214A1 (en) |
AU (1) | AU2005316396A1 (en) |
CA (1) | CA2589527A1 (en) |
CR (1) | CR9204A (en) |
EA (1) | EA200701297A1 (en) |
GT (1) | GT200500373A (en) |
IL (1) | IL183510A0 (en) |
MX (1) | MX2007007264A (en) |
NO (1) | NO20073105L (en) |
PA (1) | PA8657001A1 (en) |
PE (1) | PE20060871A1 (en) |
SV (1) | SV2006002347A (en) |
TW (1) | TW200635596A (en) |
UY (1) | UY29266A1 (en) |
WO (1) | WO2006066079A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009152166A1 (en) * | 2008-06-10 | 2009-12-17 | Anadys Pharmaceuticals, Inc. | [1,2,4]thiadiazine 1,1-dioxide compounds |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
WO2011045271A1 (en) | 2009-10-15 | 2011-04-21 | Bayer Cropscience Ag | Herbicidally active, heterocyclyl-substituted pyridazinones |
WO2011072370A1 (en) | 2009-12-18 | 2011-06-23 | Boehringer Ingelheim International Gmbh | Hcv combination therapy |
EP2494991A1 (en) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
US8741936B2 (en) | 2005-05-10 | 2014-06-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
WO2014123795A2 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014123794A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9243002B2 (en) | 2013-02-07 | 2016-01-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
AU2019203611B2 (en) * | 2014-04-29 | 2020-11-12 | Fmc Corporation | Pyridazinone herbicides |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR054214A1 (en) | 2004-12-17 | 2007-06-13 | Anadys Pharmaceuticals Inc | COMPOUNDS DERIVED FROM 1, 1 - DIOXOTIADIAZINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF INFECTION BY THE VIRUS OF HEPATITIS C. |
US20080090814A1 (en) * | 2006-06-22 | 2008-04-17 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
EP2038286B1 (en) | 2006-06-22 | 2017-03-08 | Anadys Pharmaceuticals, Inc. | Pyrro[1,2-b]pyridazinone compounds |
TW200840572A (en) | 2006-12-12 | 2008-10-16 | Anadys Pharmaceuticals Inc | 5,6-dihydro-1H-pyridin-2-one compounds |
WO2008073987A1 (en) * | 2006-12-12 | 2008-06-19 | Anadys Pharmaceuticals, Inc. | Saturated fused [1,2-b] pyridazinone compounds |
US20080188466A1 (en) * | 2006-12-21 | 2008-08-07 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
US20080275032A1 (en) * | 2006-12-29 | 2008-11-06 | Yuefen Zhou | Pyridazinone compounds |
US20080227774A1 (en) * | 2007-03-15 | 2008-09-18 | Frank Ruebsam | 5,5-disubstituted-indolizinone compounds |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
WO2008144500A2 (en) * | 2007-05-17 | 2008-11-27 | Anadys Pharmaceuticals, Inc. | 1-methyl-benzo[1,2,4]thiadiazine, 1-oxide derivatives |
ITMI20071012A1 (en) * | 2007-05-18 | 2008-11-19 | St Microelectronics Srl | MEMORY DEVICE IMPROVED AT FAST PROGRAMMING |
US7834009B2 (en) * | 2007-08-27 | 2010-11-16 | Anadys Pharmaceuticals, Inc. | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds |
TW201026675A (en) * | 2008-10-09 | 2010-07-16 | Anadys Pharmaceuticals Inc | 5,6-dihydro-1H-pyridin-2-one compounds |
EP2346329B1 (en) | 2008-10-09 | 2013-08-21 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
CN102858344A (en) | 2009-10-28 | 2013-01-02 | 安那迪斯药品股份有限公司 | Deuterated 5,6-dihydro-1h-pyridin-2-one Compounds |
WO2012158271A1 (en) | 2011-04-06 | 2012-11-22 | Anadys Pharmaceuticals, Inc. | Bridged polycyclic compounds as antiviral agents |
CN108290850A (en) * | 2015-12-07 | 2018-07-17 | Dic株式会社 | The manufacturing method of polymerizable compound |
CN105999097A (en) * | 2016-07-08 | 2016-10-12 | 王恩禄 | Traditional Chinese medicine composition for treating hepatitis B |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5954047A (en) * | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085172A1 (en) | 2000-05-10 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
US20060003346A1 (en) | 2000-08-11 | 2006-01-05 | Ashok Amin | Method for treating hepatitis |
AR036081A1 (en) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | COMPOSITE OF 1,2-DIHYDROQUINOLINE, ITS USE TO PREPARE A PHARMACEUTICAL COMPOSITION, METHODS TO PREPARE IT AND N-RENTED 2-AMINOBENZOIC ACID OF UTILITY AS INTERMEDIARY IN SUCH METHODS |
AU2002365198A1 (en) | 2001-10-30 | 2003-07-30 | Smithkline Beecham Corporation | Novel anti-infectives |
US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
BRPI0514591A (en) | 2004-08-23 | 2008-06-17 | Hoffmann La Roche | heterocyclic antiviral compounds |
AR054214A1 (en) | 2004-12-17 | 2007-06-13 | Anadys Pharmaceuticals Inc | COMPOUNDS DERIVED FROM 1, 1 - DIOXOTIADIAZINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE TREATMENT OF INFECTION BY THE VIRUS OF HEPATITIS C. |
BRPI0607533A2 (en) | 2005-04-21 | 2009-09-15 | Nippon Shinyaku Co Ltd | phthalazinone derivative, pharmaceutical composition, phosphodiesterase type 4 inhibitor, tnf-alpha production suppressant, preventive or therapeutic agent, external preparation, as well as use of said derivative |
EP1879885A1 (en) | 2005-05-04 | 2008-01-23 | F. Hoffmann-Roche AG | Heterocyclic antiviral compounds |
EP2038286B1 (en) | 2006-06-22 | 2017-03-08 | Anadys Pharmaceuticals, Inc. | Pyrro[1,2-b]pyridazinone compounds |
-
2005
- 2005-12-16 AR AR20050105305A patent/AR054214A1/en not_active Application Discontinuation
- 2005-12-16 AP AP2007004040A patent/AP2007004040A0/en unknown
- 2005-12-16 WO PCT/US2005/045588 patent/WO2006066079A2/en active Application Filing
- 2005-12-16 US US11/304,902 patent/US7425552B2/en not_active Expired - Fee Related
- 2005-12-16 GT GT200500373A patent/GT200500373A/en unknown
- 2005-12-16 CN CNA2005800430935A patent/CN101137651A/en active Pending
- 2005-12-16 AU AU2005316396A patent/AU2005316396A1/en not_active Abandoned
- 2005-12-16 CA CA002589527A patent/CA2589527A1/en not_active Abandoned
- 2005-12-16 KR KR1020077016317A patent/KR20070100743A/en not_active Application Discontinuation
- 2005-12-16 EP EP05854333A patent/EP1824847A2/en not_active Withdrawn
- 2005-12-16 JP JP2007546930A patent/JP2008526687A/en active Pending
- 2005-12-16 TW TW094144751A patent/TW200635596A/en unknown
- 2005-12-16 EA EA200701297A patent/EA200701297A1/en unknown
- 2005-12-16 MX MX2007007264A patent/MX2007007264A/en not_active Application Discontinuation
- 2005-12-19 SV SV2005002347A patent/SV2006002347A/en unknown
- 2005-12-19 PA PA20058657001A patent/PA8657001A1/en unknown
- 2005-12-20 UY UY29266A patent/UY29266A1/en not_active Application Discontinuation
-
2006
- 2006-01-03 PE PE2006000033A patent/PE20060871A1/en not_active Application Discontinuation
-
2007
- 2007-05-29 IL IL183510A patent/IL183510A0/en unknown
- 2007-06-18 NO NO20073105A patent/NO20073105L/en not_active Application Discontinuation
- 2007-06-22 CR CR9204A patent/CR9204A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5954047A (en) * | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8741936B2 (en) | 2005-05-10 | 2014-06-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US10010536B2 (en) | 2005-05-10 | 2018-07-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
EP2494991A1 (en) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
US9290450B2 (en) | 2008-06-03 | 2016-03-22 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
USRE47142E1 (en) | 2008-06-03 | 2018-11-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8222404B2 (en) | 2008-06-10 | 2012-07-17 | Anadys Pharmaceuticals, Inc. | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound |
WO2009152166A1 (en) * | 2008-06-10 | 2009-12-17 | Anadys Pharmaceuticals, Inc. | [1,2,4]thiadiazine 1,1-dioxide compounds |
US8097613B2 (en) | 2008-06-10 | 2012-01-17 | Anadys Pharmaceuticals, Inc. | [1,2,4]thiadiazine 1,1-dioxide compounds |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
WO2011045271A1 (en) | 2009-10-15 | 2011-04-21 | Bayer Cropscience Ag | Herbicidally active, heterocyclyl-substituted pyridazinones |
WO2011072370A1 (en) | 2009-12-18 | 2011-06-23 | Boehringer Ingelheim International Gmbh | Hcv combination therapy |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9675593B2 (en) | 2012-10-02 | 2017-06-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10376497B2 (en) | 2012-10-02 | 2019-08-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10898474B2 (en) | 2012-10-02 | 2021-01-26 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9243002B2 (en) | 2013-02-07 | 2016-01-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C |
US9493461B2 (en) | 2013-02-07 | 2016-11-15 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C |
US9242998B2 (en) | 2013-02-07 | 2016-01-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C |
WO2014123794A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014123795A2 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
AU2019203611B2 (en) * | 2014-04-29 | 2020-11-12 | Fmc Corporation | Pyridazinone herbicides |
Also Published As
Publication number | Publication date |
---|---|
SV2006002347A (en) | 2006-08-25 |
WO2006066079A3 (en) | 2006-12-14 |
NO20073105L (en) | 2007-09-13 |
AR054214A1 (en) | 2007-06-13 |
MX2007007264A (en) | 2007-08-14 |
CR9204A (en) | 2007-09-06 |
AP2007004040A0 (en) | 2007-06-30 |
AU2005316396A1 (en) | 2006-06-22 |
EP1824847A2 (en) | 2007-08-29 |
TW200635596A (en) | 2006-10-16 |
US7425552B2 (en) | 2008-09-16 |
UY29266A1 (en) | 2006-07-31 |
EA200701297A1 (en) | 2007-12-28 |
US20060189602A1 (en) | 2006-08-24 |
KR20070100743A (en) | 2007-10-11 |
IL183510A0 (en) | 2007-09-20 |
PA8657001A1 (en) | 2006-08-03 |
JP2008526687A (en) | 2008-07-24 |
CN101137651A (en) | 2008-03-05 |
GT200500373A (en) | 2006-10-02 |
CA2589527A1 (en) | 2006-06-22 |
PE20060871A1 (en) | 2006-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7425552B2 (en) | Pyridazinone compounds | |
CA2656000C (en) | Pyrro[1,2-b]pyridazinone compounds | |
EP2129224B1 (en) | 5,6-dihydro-1h-pyridin-2-one compounds | |
US7834009B2 (en) | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds | |
US20080292588A1 (en) | 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives | |
US20080275032A1 (en) | Pyridazinone compounds | |
US20080090814A1 (en) | Pyridazinone compounds | |
US20080227774A1 (en) | 5,5-disubstituted-indolizinone compounds | |
US20080188466A1 (en) | Pyridazinone compounds | |
US20080214529A1 (en) | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | |
WO2009152166A1 (en) | [1,2,4]thiadiazine 1,1-dioxide compounds | |
AU2007260827B2 (en) | Pyrro[1,2-b]pyridazinone compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200580043093.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 12007501133 Country of ref document: PH Ref document number: 183510 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2589527 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005854333 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007546930 Country of ref document: JP Ref document number: MX/a/2007/007264 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 555941 Country of ref document: NZ Ref document number: 2005316396 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: AP/P/2007/004040 Country of ref document: AP Ref document number: CR2007-009204 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2416/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07070591 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2005316396 Country of ref document: AU Date of ref document: 20051216 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005316396 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2007000439 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077016317 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200701432 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200701297 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 2005854333 Country of ref document: EP |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0518981 Country of ref document: BR Kind code of ref document: A2 Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL FACE A IMPOSSIBILIDADE DE ACEITACAO NA FASE NACIONAL POR NAO ATENDER O DISPOSTO NO ART. 216 DA LPI. |